Challenges in Oral Lipid-lowering Therapy: Position Document of the Spanish Society of Cardiology
Rev Esp Cardiol (Engl Ed). 2016 Nov;69(11):1083-1087.
doi: 10.1016/j.rec.2016.05.033.
Epub 2016 Sep 16.
[Article in
English,
Spanish]
Affiliations
- 1 Servicio de Cardiología, Hospital Universitario Reina Sofía, Córdoba, Spain.
- 2 Servicio de Cardiología, Hospital Universitario La Paz, Madrid, Spain.
- 3 Servicio de Cardiología, Hospital Universitario de San Juan, San Juan de Alicante, Alicante, Spain.
- 4 Servicio de Cardiología, Hospital de la Santa Creu y Sant Pau, Barcelona, Spain.
- 5 Servicio de Cardiología, Hospital Universitario de Málaga, Málaga, Spain.
- 6 Servicio de Cardiología, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain. Electronic address: jose.ramon.gonzalez.juanatey@sergas.es.
- 7 Servicio de Cardiología, Hospital Universitario Vall d'Hebron, Barcelona, Spain.
- 8 Servicio de Cardiología, Hospital Carlos III, Madrid, Spain.
- 9 Servicio de Cardiología, Hospital Virgen de la Salud, Toledo, Spain.
Abstract
Lipid-lowering therapy is one of the cornerstones of cardiovascular prevention and is one of the most effective strategies in the secondary prevention of ischemic heart disease. Nevertheless, the current treatment of lipid disorders, together with lifestyle changes, fails to achieve the targets recommended in clinical guidelines in a substantial proportion of patients. PCSK9 inhibitors have demonstrated safety and efficacy in the treatment of dyslipidemia. Due to their ability to reduce low-density lipoprotein cholesterol levels, these drugs have recently been approved for clinical use by Spanish regulatory agencies, with the aim of reducing cardiovascular risk in selected patient groups.
Keywords:
Consensus document; Documento de consenso; Inhibidores PCSK9; Lipids and ischemic heart disease; Lípidos en enfermedad coronaria; PCSK9 inhibitors.
Copyright © 2016 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.
Publication types
-
Consensus Development Conference
MeSH terms
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Cardiology
-
Cholesterol, LDL / blood
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
-
Hyperlipidemias / blood
-
Hyperlipidemias / drug therapy*
-
Hyperlipoproteinemia Type II / blood
-
Hyperlipoproteinemia Type II / drug therapy*
-
Hypolipidemic Agents / therapeutic use*
-
PCSK9 Inhibitors*
-
Patient Care Planning
-
Primary Prevention
-
Secondary Prevention
-
Societies, Medical
-
Spain
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Cholesterol, LDL
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Hypolipidemic Agents
-
PCSK9 Inhibitors
-
PCSK9 protein, human
-
evolocumab
-
alirocumab